Filing Details
- Accession Number:
- 0001610717-24-000398
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-17 16:07:16
- Reporting Period:
- 2024-07-15
- Accepted Time:
- 2024-07-17 16:07:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1628171 | Revolution Medicines Inc. | RVMD | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1462808 | Michael Stephen Kelsey | C/O Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063 | See Remarks | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-07-15 | 16,667 | $4.09 | 285,740 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-07-15 | 1,100 | $43.99 | 284,640 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-15 | 2,128 | $44.94 | 282,512 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-15 | 5,760 | $46.08 | 276,752 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-15 | 3,800 | $47.02 | 272,952 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-15 | 3,879 | $48.06 | 269,073 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-07-15 | 16,667 | $0.00 | 16,667 | $4.09 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 73,332 | 2023-03-13 | 2029-03-12 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
- Includes 95,476 restricted stock units.
- The transaction was executed in multiple trades in prices ranging from $43.37 to $44.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $44.40 to $45.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $45.60 to $46.53, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $46.62 to $47.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $47.62 to $48.47, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
